Timothy Sullivan

Timothy Sullivan

Auto-generated profile, based on publicly available information

Timothy Sullivan

Division of Infectious Diseases Icahn School of Medicine at Mount Sinai New York New York USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2005 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
ATAlphonse Taghian
Alphonse Taghian
RARita Abi-Raad
Rita Abi-Raad
SASherif I. Assaad
Sherif I. Assaad
ACAdrian Casty
Adrian Casty
MAMarek Ancukiewicz
Marek Ancukiewicz
SPSimon N. Powell
Simon N. Powell
Purpose: It has been hypothesized that tumors with high interstitial fluid pressure (IFP) and/or hypoxia respond poorly to chemotherapy (CT) because of poor drug delivery. Preclinical studies have shown that paclitaxel reduces the IFP and improves the oxygenation (pO2) of tumors. Our aim is to evaluate the IFP and pO2 before and after neoadjuvant CT using sequential paclitaxel and doxorubicin in patients with breast cancer tumors of ≥ 3 cm. Patients and Methods: Patients were randomly assigned, according to an institutional review board–approved phase II protocol, to receive neoadjuvant sequential CT consisting of either four cycles of dose-dense doxorubicin at 60 mg/m2 every 2 weeks followed by nine cycles of weekly paclitaxel at 80 mg/m2 (group 1) or vice versa, with paclitaxel administered before doxorubicin (group 2). Patients were re-evaluated clinically and radiologically. The IFP (wick-in-needle technique) and pO2 (Eppendorf) were measured in tumors at baseline and after completing the administration of the first and second drug. Results: IFP and pO2 were measured in 54 patients at baseline and after the first CT. Twenty-nine and 25 patients were randomly assigned to groups 1 and 2, respectively. Paclitaxel, when administered first, decreased the mean IFP by 36% (P = .02) and improved the tumor pO2 by almost 100% (P = .003). In contrast, doxorubicin did not have a significant effect on either parameter. This difference was independent of the tumor size or response measured by ultrasound. Conclusion: Paclitaxel significantly decreased the IFP and increased the pO2, whereas doxorubicin did not cause any significant changes. Tumor physiology could potentially be used to optimize the sequence of neoadjuvant CT in breast cancer.

1 July 2005 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
RJReshma Jagsi
Reshma Jagsi
RRRita Abi Raad
Rita Abi Raad
SGSaveli Goldberg
Saveli Goldberg
TSTimothy Sullivan
Timothy Sullivan
JMJames Michaelson
James Michaelson
ATAlphonse G. Taghian
Alphonse G. Taghian

1 October 2006 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
SFScott R. Floyd
Scott R. Floyd
TBThomas A. Buchholz
Thomas A. Buchholz
BHBruce G. Haffty
Bruce G. Haffty
SGSaveli Goldberg
Saveli Goldberg
ANAndrzej Niemierko
Andrzej Niemierko
ATAlphonse G. Taghian
Alphonse G. Taghian

24 July 2012 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
TSTimothy Sullivan
Timothy Sullivan
YAYanis Ben Amor
Yanis Ben Amor
Yanis Ben Amor and Timothy Sullivan call for more research to examine whether the diagnosis and treatment of diabetes in TB patients may improve TB outcomes and patient survival.

1 June 2020 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
RURyan C. Ungaro
Ryan C. Ungaro
TSTimothy Sullivan
Timothy Sullivan
JCJean-Frederic Colombel
Jean-Frederic Colombel
GPGopi Patel
Gopi Patel

1 October 2005 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
TSTimothy Sullivan
Timothy Sullivan
RRRita Abi Raad
Rita Abi Raad
SGSaveli Goldberg
Saveli Goldberg
SASherif I. Assaad
Sherif I. Assaad
MGMichele Gadd
Michele Gadd
ATAlphonse Taghian
Alphonse Taghian